Transmitting information to us by e-mail unilaterally does not establish an attorney-client relationship or impose an obligation on either the law firm or even the receiving lawyer to keep the transmitted information confidential. By clicking "OK", you acknowledge that we have no obligation to maintain the confidentiality of any information you submit to us unless we already represent you or unless we have agreed to receive limited confidential material/information from you as a prospective client. Thus, if you are not a client or someone we have agreed to consider as a prospective client, information you submit to us by e-mail may be disclosed to others or used against you. If you would like to discuss becoming a client, please contact one of our attorneys to arrange for a meeting or telephone conference. If you wish to disclose confidential information to a lawyer in the firm before an attorney-client relationship is established, the protections that the law firm will provide to such information from a prospective client should be discussed before such information is submitted. Thank you for your interest in Goodwin Procter.

Rina Omura

Goodwin Procter

main

Omura Rina

Paralegal Rina Omura, from Munich servces as a paralegal in the Business Law Department with an emphasis on private equity.

Rina Omura

Areas of Practice

Related Content

Goodwin Advises Sophora and Portfolio Company auxalia on the Financing of the Merger with WESTCAM

Goodwin Advises LEA Partners on the Financing of the Acquisition of PAQATO

Goodwin advises CAPZA Private Debt on refinancing for the acquisition of Primed Group

Goodwin Advises Armira On The Acquisition Financing For A Majority Stake In INTEC Industrie-Technik

Goodwin advises Eurazeo on refinancing and add-on acquisition financing of salestech group

Goodwin Advises Armira on the Financing of the Partnership With almapharm

Goodwin Advises Sophora on Refinancing of auxalia and Financing of the Acquisition of ICN Group

Goodwin Advises PINOVA Capital on the Financing of the Acquisition of NEUROMEDEX

Private Equity